JPRN-jRCT2071230002已完成1 期
Single and multiple dose escalation study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of BAY 3283142 given as oral tablets in Japanese healthy male participants in a randomized, placebo-controlled, single-blind, group-comparison design
Myoishi Masafumi0 个研究点目标入组 36 人开始时间: 2023年4月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 50age old（—）
- 性别
- Male
入选标准
- •Participant must be 20 to 50 years of age inclusive, at the time of signing the informed consent.
- •- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12 lead ECG.
- •- Race: Japanese.
- •- body mass index (BMI) within the range 18.0 and 29.9 kg/m2 (inclusive).
- •- Body weight equal or above 55 kg (inclusive).
- •- Male: Contraceptive use by men and female partners of male participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •- Capable of giving signed informed consent.
排除标准
- •- Medical disorder, condition, or history of such that would impair the participants ability to participate or complete this study in the opinion of the investigator.
- •- A history of clinically relevant diseases of any organs.
- •- Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study interventions will not be normal.
- •- Participants with thyroid disorders as evidenced by assessment of thyroid stimulating hormone levels outside the normal reference range.
- •- Known hypersensitivity to the study interventions (active substances or excipients of the preparations, e.g., lactose).
- •- Known severe allergies (e.g., allergies to more than 3 allergens, allergies affecting the lower respiratory tract - allergic asthma, allergies requiring therapy with corticosteroids), urticaria or significant non-allergic drug reactions.
- •- Relevant diseases within the last 4 weeks prior to the first intake of study intervention.
- •- Febrile illness within 2 weeks before the first intake of study intervention.
- •- Known tendency for vasovagal reactions (e.g., after venipuncture) or history of syncope.
- •- History of gastrointestinal surgery, with the exception of appendectomy (surgery at least 12 months before screening) and inguinal hernia repair (the surgery at least 12 months before screening with the documentation of no intestine necrosis and no intestine segment resection, and participants must be fully recovered and have no signs or symptoms).
- •- Acute diarrhea or constipation within 14 days before the first intake of study intervention.
- •- Regular use of medicines.
- •- Use of any other systemic or topical medicines or substances which oppose the study objectives.
- •- Regular use of therapeutic or recreational drugs, e.g., carnitine products, anabolics, high dose vitamins.
- •- Excluded therapies (e.g., physiotherapy, acupuncture, etc.) within 1 week before the first intake of study intervention.
- •- Participation in another clinical study of an investigational drug (last dose) within 90 days or 5 half lives of the investigational drug, whichever is longer, before the first dose of this study.
- •- Exclusion periods from other studies or simultaneous participation in other clinical studies.
- •- Previous treatment during this study (allowing previously treated participants to be re included into the study may lead to bias).
- •- Clinically relevant findings in the 12-lead ECG such as a second- or third-degree atrioventricular block, prolongation of the QRS complex over or equal to 120 msec, or of the QTcF or QTcB intervals over 450 msec.
- •- Clinically relevant arrhythmic disturbances as found in the 12-lead ECGs (especially repeated supra- and ventricular ectopic beats - Lown classification grade 2 or more); known congenital QT prolongation.
- •- Systolic blood pressure (SBP) below 100 or above 140 mmHg (after 15 min of supine rest).
- •- Diastolic blood pressure (DBP) below 50 or above 90 mmHg (after 15 min of supine rest).
- •- Heart rate (HR) below 45 or above 90 bpm (after 15 min of supine rest).
- •- Clinically relevant findings in the physical examination.
- •- Positive results for HBsAg, anti-HCV, HIV antigen and antibody, and syphilis (cardiolipin-lecithin antigen, Treponema pallidum antibody).
- •- Creatine kinase (CK) above upper limit of normal (ULN), except marginal explainable changes which are expected to normalize before study intervention intake.
- •- Lipase and amylase above ULN (except isolated marginal increases
研究者
相似试验
已完成
1 期
A study in healthy subjects to see the effects of the test medicine ALKS 2680 in single and multi-dose regimePhase 1 drug studyNervous System DiseasesISRCTN98204977Alkermes (United States)147
招募中
1 期
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease (I8G-MC-LMDD)Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's DiseaseJPRN-jRCT2080223501Eli Lilly Japan K.K.
招募中
1 期
A single- and multiple ascending dose study of KP-910 in healthy adult males and healthy elderly males.JPRN-jRCT2071230041Murakami Harumi96
已完成
不适用
Simultaneous boost intensity-modulated radiotherapy for locally advanced cervical cancerCervical cancerCancerISRCTN76100993Barts and The London NHS Trust (UK)44
招募中
1 期
A Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of SZN-043, a Novel Bispecific Fusion Protein Targeting ASGR1 and ZNRF3/RNF43, in Healthy Volunteers and Subjects with Liver CirrhosisAlcoholic HepatitisInflammatory and Immune System - Other inflammatory or immune system disordersLiver CirrhosisACTRN12622000392763Surrozen Operating, Inc.40